The concept and evolution of involved site radiation therapy for lymphoma

International Journal of Clinical Oncology

Volumn 20, Issue 5, 2015, Pages 849-854

  Specht, Lena ^a   Yahalom, Joachim ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Lymphoma; Radiation therapy

Indexed keywords

CANCER PATIENT; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INVOLVED NODE RADIATION THERAPY; INVOLVED SITE RADIATION THERAPY; LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; CONFORMAL RADIOTHERAPY; LYMPH NODE; LYMPHATIC METASTASIS; PATHOLOGY; PROCEDURES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING SYSTEM; THREE DIMENSIONAL IMAGING; TUMOR VOLUME;

HUMANS; IMAGING, THREE-DIMENSIONAL; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOMA; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; TUMOR BURDEN;

EID: 84942982091     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-015-0863-y     Document Type: Review

References (83)

1. Specht L (2009) The history of radiation therapy of lymphomas and description of early trials. In: Armitage JO, Coiffier B, Dalla-Favera R, Harris N, Mauch PM (eds) Non-Hodgkin’s Lymphomas, 2nd edn. Lippincott Williams & Wilkins, udg, Baltimore, pp 12–24
2. Berven E (1932) Le traitement radiologique des tumeurs malgnes de la cavité buccale. Acta Radiol 13:213–231
3. Decker FH, Leddy ET, Desjardins AU (1938) Leukopenia and leukocytosis in lymphoblastoma: their reaction to Roentgen therapy. Am J Roentgenol 39:747–766
4. Finzi NS (1938) The Roentgen treatment of lymphadenoma. Am J Roentgenol 39:261–262
5. Hellman S, Chaffey JT, Rosenthal DS et al (1977) The place of radiation therapy in the treatment of non-Hodgkin’s lymphomas. Cancer 39:843–851
6. Musshoff K, Schmidt-Vollmer H (1975) Prognostic significance of primary site after radiotherapy in non-Hodgkin’s lymphomata. Br J Cancer 31:425–434
7. Peters MV, Middlemiss KCH (1958) A study of Hodgkin’s disease treated by irradiation. Am J Roentgenol 79:114–121
8. Rosenberg SA, Dorfman RF, Kaplan HS (1975) A summary of the results of a review of 405 patients with non-Hodgkin’s lymphoma at Stanford University. Br J Cancer 31:168–173
9. Sutcliffe SB, Gospodarowicz MK, Bush RS et al (1985) Role of radiation therapy in localized non-Hodgkin’s lymphoma. Radiother Oncol 4:211–223
10. Tubiana M, Carde P, Burgers JM et al (1986) Prognostic factors in non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 12:503–514
11. Hoppe RT, Horning SJ, Rosenberg SA (1985) The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin’s disease. Cancer Surv 4:459–475
12. Specht L, Gray RG, Clarke MJ et al (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol 16:830–843
13. Yahalom J, Varsos G, Fuks Z et al (1993) Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 71:2342–2350
14. Aleman BM, van den Belt-Dusebout AW, de Bruin ML et al (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878–1886
15. Cutter DJ, Schaapveld M, Darby SC et al (2015) Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 107(4):djv008. doi:10.1093/jnci/djv008
16. Daniels LA, Krol AD, Schaapveld M et al (2013) Long-term risk of secondary skin cancers after radiation therapy for Hodgkin’s lymphoma. Radiother Oncol 109:140–145
17. de Bruin ML, Sparidans J, van’t Veer MB et al (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27:4239–4246
18. de Bruin ML, Dorresteijn LD, van’t Veer MB et al (2009) Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 101:928–937
19. de Bruin ML, Burgers JA, Baas P et al (2009) Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood 113:3679–3681
20. Dores GM, Metayer C, Curtis RE et al (2002) Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 20:3484–3494
21. Dores GM, Curtis RE, van Leeuwen FE et al (2014) Pancreatic cancer risk after treatment of Hodgkin lymphoma. Ann Oncol 25:2073–2079
22. Hodgson DC, Gilbert ES, Dores GM et al (2007) Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol 25:1489–1497
23. Mauch P, Ng A, Aleman B et al (2005) Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin’s disease: July 9–16, 2003, Bellagio, Italy. Eur J Haematol 75(Suppl 66):68–76
24. Morton LM, Dores GM, Curtis RE et al (2013) Stomach cancer risk after treatment for hodgkin lymphoma. J Clin Oncol 31:3369–3377
25. Morton LM, Gilbert ES, Stovall M et al (2014) Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica 99:e193–e196
26. Swerdlow AJ, Cooke R, Bates A et al (2012) Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin’s lymphoma in England and Wales: a National Cohort Study. J Clin Oncol 30:2745–2752
27. Travis LB, Curtis RE, Glimelius B et al (1993) Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst 85:1932–1937
28. Travis LB, Gospodarowicz M, Curtis RE et al (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 94:182–192
29. Travis LB, Hill D, Dores GM et al (2005) Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97:1428–1437
30. Travis LB, Ng AK, Allan JM et al (2012) Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 104:357–370
31. van Leeuwen FE, Klokman WJ, Stovall M et al (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 95:971–980
32. van Nimwegen FA, Schaapveld M, Janus CP et al (2014) Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma. J Clin Oncol 32:3257–3263
33. van Nimwegen FA, Schaapveld M, Janus CP et al (2015) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175:1007–1017
34. Kaplan HS, Rosenberg SA (1966) The treatment of Hodgkin’s disease. Med Clin North Am 50:1591–1610
35. Shahidi M, Kamangari N, Ashley S et al (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5
36. Yahalom J, Mauch P (2002) The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol 13(Suppl 1):79–83
37. Girinsky T, Van Der Maazen R, Specht L et al (2006) involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277
38. Girinsky T, Ghalibafian M, Bonniaud G et al (2007) Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 85:178–186
39. Girinsky T, Ghalibafian M (2007) Radiotherapy of hodgkin lymphoma: indications, new fields, and techniques. Semin Radiat Oncol 17:206–222
40. Girinsky T, Specht L, Ghalibafian M et al (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202–210
41. Girinsky T, Auperin A, Ribrag V et al (2014) Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients. Int J Radiat Oncol Biol Phys 89:1047–1052
42. DeLuca P, Jones D, Gahbauer R et al (2010) Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). J ICRU 10:1–106
43. Raemaekers JM, Andre MP, Federico M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32: 1188–1194
44. Maraldo MV, Aznar MC, Vogelius IR et al (2013) Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma. Int J Radiat Oncol Biol Phys 85:1057–1065
45. Verhappen MH, Poortmans PM, Raaijmakers E et al (2013) Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin’s lymphoma. Radiother Oncol 109:133–139
46. Campbell BA, Voss N, Woods R et al (2010) Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 116:3797–3806
47. Eich HT, Muller RP, Engenhart-Cabillic R et al (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184:406–410
48. Hoskin PJ, Diez P, Williams M et al (2013) Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) 25:49–58
49. Illidge T, Specht L, Yahalom J et al (2014) Modern radiation therapy for nodal non Hodgkin lymphoma—target definition and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:49–58
50. Specht L, Yahalom J, Illidge T et al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862
51. Yahalom J, Illidge T, Specht L et al (2015) Modern radiation therapy for extranodal lymphomas: field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 92:11–31
52. NCCN Clinical Practice Guidelines in Oncology, Non-Hodgkin’s Lymphomas, Version 2.2015
53. Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ, Connors JM (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26:5170–5174
54. Campbell BA, Connors JM, Gascoyne RD, Morris WJ, Pickles T, Sehn LH (2012) Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer 118:4156–4165
55. Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, Lessard NA, Lefkopoulos D, Girinsky T (2011) Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 80:199–205
56. Paumier A, Khodari W, Beaudre A, Ghalibafian M, Blanchard P, al HH, Bhari M, Lessard N, Girinsky T (2011) Intensity-modulated radiotherapy and involved-node concept in patients with Hodgkin lymphoma: experience of the Gustave-Roussy Institute. Cancer Radiother 15: 709–715
57. Paumier A, Bakkour M, Ghalibafian M, Beaudre A, Blanchard P, Martinetti F, Girinsky T (2012) Involved-node radiotherapy combined with deep-inspiration breath-hold technique in patients with Hodgkin lymphoma]. Cancer Radiother 16:85–90
58. Milgrom SA, Yahalom J (2013) Indolent non-Hodgkin lymphoma primarily involving the hard palate: outcome following radiotherapy. Leuk Lymphoma 54:1208–1211
59. Campbell BA, Hornby C, Cunninghame J, Burns M, MacManus M, Ryan G, Lau E, Seymour JF, Wirth A (2012) Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 23:1259–1266
60. Jorgensen AY, Maraldo MV, Brodin NP et al (2013) The effect on esophagus after different radiotherapy techniques for early stage Hodgkin’s lymphoma. Acta Oncol 52:1559–1565
61. Koeck J, Abo-Madyan Y, Lohr F et al (2012) Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 83:268–276
62. Lohr F, Georg D, Cozzi L et al (2014) Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open? Strahlenther Onkol 190:864–871
63. Maraldo MV, Brodin NP, Vogelius IR et al (2012) Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 83:1232–1237
64. Maraldo MV, Brodin P, Aznar MC et al (2013) Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment? Int J Radiat Oncol Biol Phys 87:297–303
65. Maraldo MV, Brodin NP, Aznar MC et al (2013) Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol 24:2113–2118
66. Maraldo MV, Jorgensen M, Brodin NP et al (2014) The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 61:717–722
67. Maraldo MV, Brodin NP, Aznar MC et al (2014) Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy. Radiother Oncol 110:441–447
68. Reymen B, Spiessens S, Lievens Y (2010) Radiotherapy in early stage Hodgkin’s lymphoma: the importance of volume and treatment position. Radiother Oncol 95:225–228
69. Weber DC, Peguret N, Dipasquale G et al (2009) Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 75:1578–1586
70. Weber DC, Johanson S, Peguret N et al (2011) Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 81:490–497
71. Xu Y, Wang H, Zhou S et al (2013) Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 54:1396–1404
72. Aznar MC, Maraldo MV, Schut DA et al (2015) Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys 92:169–174
73. Fiandra C, Filippi AR, Catuzzo P, et al (2012) Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin’s Lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 7: 186
74. Filippi AR, Ragona R, Fusella M et al (2013) Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Pract Radiat Oncol 3:216–222
75. Filippi AR, Ragona R, Piva C et al (2015) Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk. Int J Radiat Oncol Biol Phys 92:161–168
76. Hoppe BS, Flampouri S, Su Z et al (2012) Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 84:449–455
77. Hoppe BS, Flampouri S, Su Z et al (2012) Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study. Int J Radiat Oncol Biol Phys 83:260–267
78. Hoppe BS, Flampouri S, Zaiden R et al (2014) Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. Int J Radiat Oncol Biol Phys 89:1053–1059
79. Maraldo MV, Specht L (2014) A decade of comparative dose planning studies for early-stage Hodgkin lymphoma: what can we learn? Int J Radiat Oncol Biol Phys 90:1126–1135
80. Maraldo MV, Dabaja BS, Filippi AR et al (2015) Radiation therapy planning for early-stage hodgkin lymphoma: experience of the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 92:144–152
81. Petersen PM, Aznar MC, Berthelsen AK et al (2015) Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol 54:60–66
82. Schneider U, Lomax A, Lombriser N (2000) Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin’s disease with photon and proton radiation. Radiat Res 154:382–388
83. Schneider U, Sumila M, Robotka J et al (2014) Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study. Radiat Oncol 9:58